摘要
背景:家养,野生,入侵和圈养动物的种群控制是对公共卫生,动物福利和经济具有重要意义的全球性问题。迫切需要有效,安全和廉价的避孕技术来解决这个问题。旨在刺激免疫系统以阻断关键的生殖事件并抑制生育力的避孕疫苗可以提供解决方案。丝状噬菌体可以用作开发这种疫苗的平台。 目的:在这篇综述中,作者强调了丝状噬菌体的结构和免疫原性,并讨论了噬菌体肽疫苗在动物免疫避孕技术发展中的应用。 结果:噬菌体可以被设计成展示融合(非噬菌体)肽作为外壳蛋白。这种修饰可以通过噬菌体DNA的遗传操作,或通过合成肽与噬菌体表面蛋白的化学偶联实现。具有抗原决定簇的噬菌体融合物诱导动物体液以及细胞介导的免疫应答,使其作为疫苗具有吸引力。噬菌体平台的其他优点包括环境稳定性,低成本以及免疫动物和施用疫苗的那些的安全性。 结论:丝状噬菌体是可用于疫苗开发的可行平台,可以通过分子和机体特异性进行工程设计。基于噬菌体的疫苗可以以低成本大量生产,是环境稳定的,并且当通过多种途径施用时是免疫原性的。这些特征对避孕疫苗在动物应用中的操作实用性是必不可少的。噬菌体平台的适应性也使其对人免疫避孕剂的设计具有吸引力。
关键词: 动物种群控制,噬菌体,避孕,噬菌体融合,噬菌体免疫原性,疫苗。
Current Medicinal Chemistry
Title:Immunocontraception: Filamentous Bacteriophage as a Platform for Vaccine Development
Volume: 24 Issue: 35
关键词: 动物种群控制,噬菌体,避孕,噬菌体融合,噬菌体免疫原性,疫苗。
摘要: Background: Population control of domestic, wild, invasive, and captive animal species is a global issue of importance to public health, animal welfare and the economy. There is pressing need for effective, safe, and inexpensive contraceptive technologies to address this problem. Contraceptive vaccines, designed to stimulate the immune system in order to block critical reproductive events and suppress fertility, may provide a solution. Filamentous bacteriophages can be used as platforms for development of such vaccines.
Objective: In this review authors highlight structural and immunogenic properties of filamentous phages, and discuss applications of phage-peptide vaccines for advancement of immunocontraception technology in animals.
Results: Phages can be engineered to display fusion (non-phage) peptides as coat proteins. Such modifications can be accomplished via genetic manipulation of phage DNA, or by chemical conjugation of synthetic peptides to phage surface proteins. Phage fusions with antigenic determinants induce humoral as well as cell-mediated immune responses in animals, making them attractive as vaccines. Additional advantages of the phage platform include environmental stability, low cost, and safety for immunized animals and those administering the vaccines.
Conclusion: Filamentous phages are viable platforms for vaccine development that can be engineered with molecular and organismal specificity. Phage-based vaccines can be produced in abundance at low cost, are environmentally stable, and are immunogenic when administered via multiple routes. These features are essential for a contraceptive vaccine to be operationally practical in animal applications. Adaptability of the phage platform also makes it attractive for design of human immunocontraceptive agents.
Export Options
About this article
Cite this article as:
Immunocontraception: Filamentous Bacteriophage as a Platform for Vaccine Development, Current Medicinal Chemistry 2017; 24 (35) . https://dx.doi.org/10.2174/0929867324666170911160426
DOI https://dx.doi.org/10.2174/0929867324666170911160426 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
DNA Topoisomerase II Enzymes as Molecular Targets for Cancer Chemotherapy
Current Cancer Drug Targets Familial Colorectal Cancer Type X
Current Genomics Comparison of the Growth Curves of Cancer Cells and Cancer Stem Cells
Current Stem Cell Research & Therapy Age-Related Changes in P-Glycoprotein Expression in Senescence- Accelerated Mouse
Current Aging Science Statins-Mediated Inhibition of Rho GTPases as a Potential Tool in Anti-Tumor Therapy
Mini-Reviews in Medicinal Chemistry Biotechnological Engineering of Heparin/Heparan Sulphate: A Novel Area of Multi-Target Drug Discovery
Current Pharmaceutical Design C60 Fullerene Derivatized Nanoparticles and their Application to Therapeutics
Recent Patents on Nanotechnology Novel Analogues of CC-1065 and the Duocarmycins for the Use in Targeted Tumour Therapies
Anti-Cancer Agents in Medicinal Chemistry Noscapine and its Analogs as Chemotherapeutic Agent: Current updates
Current Topics in Medicinal Chemistry IP6 & Inositol in Cancer Prevention and Therapy
Current Cancer Therapy Reviews Effective Inhibition of Foam Cells Formation by Tanshinone IIA in RAW264.7 Macrophages Induced with LDL Isolated from Hypercholesterolemia Patients: A Proteomic Analysis
Current Proteomics Wound Healing Effect of an in Situ Forming Hydrogel Loading Curcumin-Phospholipid Complex
Current Drug Delivery Pyrazole Substituted 9-Anilinoacridines as HER2 Inhibitors Targeting Breast Cancer - An <i>in-silico</i> approach
Current Drug Research Reviews Molecular Diversity of Hydroxamic Acids: Part II. Potential Therapeutic Applications
Mini-Reviews in Medicinal Chemistry NF-κ B and Rheumatic Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Ultrasound Promoted Green Synthesis, Docking Study of Indole Spliced Thiadiazole, α-amino Phosphonates as Anticancer Agents and Antityrosinase Agents
Anti-Cancer Agents in Medicinal Chemistry Anti-Angiogenic Treatment for Exudative Age-Related Macular Degeneration: New Strategies are Underway
Current Angiogenesis (Discontinued) Cyclooxygenase as a Target for Colorectal Cancer Chemoprevention
Current Drug Targets Genetic and Pharmacological Modulation of Dendritic Cell-T Cell Interactions as a Therapeutic Strategy for Systemic Lupus Erythematosus
Current Gene Therapy Nanocarriers for Systemic and Mucosal Vaccine Delivery
Recent Patents on Drug Delivery & Formulation